What is the cure for nasal allergy
If you are love most people, you hate the thought of walking into a crowded waiting room at the doctor’s office – and facing a endless wait before the doctor or nurse practitioner can see you. After every, your time is just as valuable as theirs. Maybe that’s why thousands of patients own chosen Allergic & Asthmatic Comprehensive Care of New Jersey (AACCNJ).
At AACCNJ, our medical director, Eric S.
Applebaum, MD, schedules and sees one patient at a time. That’s how he has done it for over 20 years. Dr. Applebaum strives to be on time for your scheduled appointment as he also understands the worth of your time.
It’s not unusual for Dr. Applebaum to spend a full hour with each patient, answering their questions, explaining treatment options and simply getting to know them as individuals. He believes that’s the best way to accurately diagnose their conditions and assist them overcome the limitations their allergies and asthma put upon them.
Applebaum provides comprehensive care for the full spectrum of allergy and asthma conditions and symptoms, including:
• Food allergies • Seasonal allergies • Pollen allergy • Atopic dermatitis • Eczema • Skin rash • Hives
• Allergic rhinitis (hay fever) • Chronic sinusitis • Nasal congestion • Asthma • Coughing • Wheezing
AACCNJ serves the Mountain Lakes and Parsippany Troy Hills communities of Parsippany, Denville, Montville (Morris County, NJ), Passaic (Passaic County, NJ).
Discover today’s most effective allergy and asthma treatment.
Believe Eric S. Applebaum, MD, for comprehensive allergy, asthma and immunology care and advanced solutions. Call us at 973.335.1700 in Parsippany or use our online Request an Appointment form to schedule your consultation.
HUENENBERG, Switzerland—(BUSINESS WIRE)—Alcon, Inc. (NYSE: ACL — News) announced today that the U.S. Food and Drug istration (FDA) has approved PATANASE® (olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE® nasal spray, an extension to Alcon’s market-leading ocular allergy product line, will be available in May of this year.
· U.S. Food and Drug istration has approved PATANASE nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
(Photo: Trade Wire). View Multimedia Gallery
“We glance forward to providing doctors the chance to prescribe PATANASE® to their patients who need and desire a fast-acting nasal spray that quickly relieves symptoms,” said Kevin Buehler, Alcon’s senior vice president, global markets and chief marketing officer. “We are excited to enter the nasal market and are confident that this new addition will continue to grow our topical allergy franchise.”
FDA approval of PATANASE® nasal spray was based primarily on multiple clinical studies for the evaluation of safety, efficacy and onset of action. The studies were two-week, randomized, double-blind clinical trials in seasonal allergic rhinitis patients and were conducted to determine the ability of PATANASE® to relieve allergy symptoms based on entire nasal symptom scores (TNSS, a composite of stuffy, runny, itchy nose and sneezing).
The results of these clinical studies were that patients treated with PATANASE®, two sprays per nostril, twice daily, demonstrated significantly greater decreases in TNSS compared to the placebo nasal spray.
Additionally, onset of action was evaluated in three environmental exposure unit studies. In these studies, patients with seasonal allergic rhinitis were exposed to high levels of pollen and then treated with either PATANASE® or placebo nasal spray, two sprays in each nostril, after which they self-reported their allergy symptoms hourly for the subsequent 12 hours. PATANASE® nasal spray was found to own an onset of action of 30 minutes and a 12 hour duration of affect after dosing, which was statistically significant compared to the placebo spray.
«For patients who suffer every allergy season with symptoms that make life in those months miserable, PATANASE® offers relief beginning in minutes in a convenient steroid-free nasal spray,» said Eli Meltzer, M.D., Medical Group and Research Middle, A.P.C., San Diego, CA, and lead investigator on one study submitted to the FDA. “The fact that it works quickly is significant. Patients in our quick paced society desire rapid improvement and relief from their nasal allergies.”
About PATANASE® Nasal Spray
PATANASE® nasal spray is indicated for patients 12 years of age and older for the relief of symptoms of seasonal allergic rhinitis.
Nasal allergy symptoms are measured by the patient’s Entire Nasal Symptom Score (TNSS) which is a combination of stuffy, runny, itchy nose and sneezing. PATANASE® is intended only for intranasal istration. The most common side effects experienced with the use of PATANASE® include: bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and urinary tract infection.
About Seasonal Allergic Rhinitis
Seasonal allergic rhinitis, also known as “hay fever,” refers to an allergic complicated of symptoms caused by sensitivity to seasonal pollens.
Symptoms may include congestion, sneezing, itchy nose, runny nose, watery eyes and itchy eyes.
According to the American College of Allergy, Asthma & Immunology (ACAAI), allergies affect an estimated 40 to 50 million people in the United States. Allergies are not only bothersome, but own been linked to a variety of common and serious chronic respiratory illnesses, such as sinusitis and asthma. In addition, they may interfere with day-to-day activities or lessen the quality of life.
About Alcon (NYSE: ACL — News)
Alcon, Inc. is the world’s leading eye care company, with sales of approximately $5.6 billion in 2007.
Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye.
Caution Concerning Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially diverse from any future results, performances or achievements expressed or implied by our forward-looking statements, specifically in regard to the future sales and profits derived from PATANASE®.
These statements reflect the views of our management as of the date of this press release with honor to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not put undue reliance on these forward-looking statements.
You should read this press release with the understanding that our actual future results may be materially diverse from what we expect. Except to the extent required under the federal securities laws and the rules an regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5659158
Alcon Doug MacHatton, (001) 817-551-8974 Vice President, Investor Relations and Corporate Communications [email protected] or Kathleen Golden, (001) 817-551-4963 Manager, Corporate Communications [email protected] www.alcon.com
Source: Alcon, Inc.
Back to news
How to Stay Healthy, Breathe Easier, and Feel Energetic This Winter
Indoor allergies, freezing weather, less sunlight — winter can make it hard to stay well mentally and physically. Discover out how to protect yourself against seasonal allergies, the winter blahs, freezing winds, comfort-eating traps, and fatigue this year.
Learn More About the Ultimate Winter Wellness Guide
Sinusitis can be a confusing thing to treat for anyone.
Because a sinus infection can be so easily confused with a common freezing or an allergy, figuring out the best way to alleviate your symptoms can be difficult.
Even more challenging, a sinus infection can evolve over time from a viral infection to a bacterial infection, or even from a short-term acute infection to a long-term chronic illness.
We own provided for you the best sources of information on sinus infections to assist you rapidly define your ailment and get the best and most efficient treatment possible.
The Best Research Resources
American Academy of Allergy, Asthma, and Immunology
This academy’s website provides valuable information to assist readers determine the difference between colds, allergies, and sinusitis.
A primer guide on sinusitis also provides more specific information about the chronic version of the illness. Additional resources include a «virtual allergist» that helps you to review your symptoms, as well as a database on pollen counts.
American College of Allergy, Asthma, and Immunology (ACAAI)
In addition to providing a comprehensive guide on sinus infections, the ACAAI website also contains a wealth of information on allergies, asthma, and immunology.
The site’s useful tools include a symptom checker, a way to search for an allergist in your area, and a function that allows you to ask an allergist questions about your symptoms.
Asthma and Allergy Foundation of America (AAFA)
For allergy sufferers, the AAFA website contains an easy-to-understand primer on sinusitis. It also provides comprehensive information on various types of allergies, including those with risk factors for sinusitis.
Centers for Disease Control and Prevention (CDC)
The CDC website provides basic information on sinus infections and other respiratory illnesses, such as common colds, bronchitis, ear infections, flu, and sore throat.
It offers guidance on how to get symptom relief for those illnesses, as well as preventative tips on practicing good hand hygiene, and a recommended immunization schedule.
U.S. National Library of Medicine
National Library of Medicine is the world’s largest biomedical library. As part of the National Institutes of Health, their website provides the basics on sinus infection. It also contains a number of links to join you with more information on treatments, diagnostic procedures, and related issues.
Favorite Resources for Finding a Specialist
American Rhinologic Society
Through research, education, and advocacy, the American Rhinologic Society is devoted to serving patients with nose, sinus, and skull base disorders.
Their website’s thorough coverage of sinus-related issues includes rarer conditions, such as fungal sinusitis, which are often excluded from other informational sites. It also provides a valuable search tool to discover a doctor, as well as links to other medical societies and resources that are useful for patients.
Their website contains an exhaustive guide on sinusitis and an easy-to-use «Find a Doctor» search tool.
ENThealth provides useful information on how the ear, nose, and throat (ENT) are all connected, along with information about sinusitis and other related illnesses and symptoms, such as rhinitis, deviated septum, and postnasal drip.
As part of the American Academy of Otolaryngology — Head and Neck Surgery, this website is equipped with the ability to assist you discover an ENT specialist in your area.
Sinusitis: A Treatment Plan That Works
for asthma and allergies too
sinusitis, allergy ,asthma, sinus infection,
Wellington S. Tichenor, M.D.
642 Park Avenue
New York, New York
This is an extremely comprehensive website which explores the symptoms and treatment of sinusitis, andother sinus diseases, as well as the interrelated problems of allergy and asthma.
It was originally written and is continously revised by Dr. Tichenor, who maintains a private practice in New York. It is primarily designed for the layperson wanting detailed information about sinusitis, although there is also extensive information for physicians aboutsinusitis. There is also information about techniques for endoscopic sinus surgery including images and explanations of image guided surgery.
This information should not be construed in any way as being specificmedical advice. Every information contained in this website is supplied for general informational purposes.
It should not be used asspecific medical information for any individual, as such information can only be supplied by a physician. You should consult with a physician regarding any information contained within this website in order to obtain optimaltreatment. If you
Go To The Table ofContents
you acknowledge the above and consent to comply.
Any comments on this site would be appreciated. Please send mail
to [email protected] Wewill attempt to answer as many
questions as is feasible personally, but are obviously limited
due to time constraints.
Any items of general interest will be
included within the website.
Last modified December 9, 2018
The contents of sinuses.com © 1996-2018 by Wellington S.Tichenor, M.D. Reproduction for educational, not-for-profit purposes is permitted if this source is credited and the author of this websiteis notified of any reproduction for other than personal use. If used on the internet, a link would be appreciated.
SAN DIEGO—(BUSINESS WIRE)—Innovus Pharmaceuticals, Inc. («Innovus Pharma» or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that its FlutiCare® OTC product for the relief of seasonal allergies is currently ranked #2 behind Flonase® in Amazon®’s Fluticasone Propionate and Allergy Nasal Spray categories.
In addition, FlutiCare® is currently ranked #6 in Amazon’s Best Moisturizing Nasal Sprays category, #11 in the Best Allergy Medicine category and #41 in the Sinus Medicine category. To meet the growing demand on Amazon® for FlutiCare®, Innovus Pharma placed an additional order of 220,000 units with its manufacturer.
FlutiCare® contains the most prescribed nasal steroid athletic pharmaceutical ingredient (“API”) and form for nasal allergy relief over the final 7 years.
FlutiCare® is available OTC with the same prescription strength and same delivery method as Flonase®* and ClariSpray®*. The Company currently believes that FlutiCare® is the most affordable fluticasone propionate nasal spray on the market and is now available in a one dose, 30 Day (120 Sprays) treatment and is the only one providing a monthly autoship plan.
“We are extremely excited to announce the current high ranking of our FlutiCare® product in certain Amazon indication categories,” said Dr.
Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “FlutiCare® traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1 and the number of units we sell has continued to grow. As sales of the product are increasing significantly, we felt it was necessary to increase our supply of this product to meet our consumers’ growing demand,” he continued.
FlutiCare® is a nasal spray, which provides 50 micrograms of fluticasone propionate (“USP”) per spray, a nasal corticosteroid that provides 24-hour temporary relief of seasonal and perennial nasal allergy symptoms.
FlutiCare® can be used to relieve both indoor and outdoor nasal allergy symptoms caused by pollen, dust, animal dander, and other indoor and outdoor allergens.
Nasal allergy symptoms include nasal congestion, runny nose, sneezing, itchy nose, etc.
FlutiCare® contains the nasal steroid API that is physician recommended and consumer preferred.
- #1 nasal steroid athletic prescribed by physicians;
- Familiar to patients, comfort of a known & trusted medicine;
- #1 form used by patients;
- Engrained in patients’ allergy management; and
- Effective and safe.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases.
Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products.
The Company is actively pursuing opportunities where existing prescription drugs own recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.xyralid.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are exterior the control of the Company, including, but not limited to, projected revenues from its FlutiCare® product, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives.
Readers are cautioned not to put undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
*Flonase® is a registered trademark of GSK and ClariSpray® is a registered trademark of Bayer.
Advanced allergy and asthma care with an old-fashioned personal touch